Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
US11702659B2 · kind B2 · utility
6Cited by
70References
30Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 22, 2022 |
| Grant date | Jul 18, 2023 |
| Priority date | — |
| Expiry date | Jun 22, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/32
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.